IL6 and COVID-19: Uncontrolled exploratory study showed that nebulized IFN-α2b in adult patients hospitalized with COVID-19 significantly reduced the duration of the detectable virus in the upper respiratory tract and duration of elevated levels of inflammatory markers (IL-6 and CRP) in the blood [59].